

Timothy W Synold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4347050/publications.pdf>

Version: 2024-02-01

104
papers

4,885
citations

101496

36
h-index

98753

67
g-index

104
all docs

104
docs citations

104
times ranked

6326
citing authors

#	ARTICLE	IF	CITATIONS
1	The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. <i>Nature Medicine</i> , 2001, 7, 584-590.	15.2	798
2	Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 31, 229-239.	1.1	208
3	The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation. <i>Clinical Cancer Research</i> , 2009, 15, 7092-7098.	3.2	194
4	Neural Stem Cell-Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. <i>Science Translational Medicine</i> , 2013, 5, 184ra59.	5.8	194
5	First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. <i>Investigational New Drugs</i> , 2013, 31, 986-1000.	1.2	187
6	Peptide Mimetic HIV Protease Inhibitors Are Ligands for the Orphan Receptor SXR. <i>Journal of Biological Chemistry</i> , 2001, 276, 33309-33312.	1.6	168
7	Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 1997, 336, 1781-1787.	13.9	158
8	DNA lesions induced by UV A1 and B radiation in human cells: Comparative analyses in the overall genome and in the p53 tumor suppressor gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10058-10063.	3.3	139
9	Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. <i>Clinical Cancer Research</i> , 2017, 23, 2951-2960.	3.2	121
10	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1994, 125, 642-649.	0.9	119
11	The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial. <i>Clinical Cancer Research</i> , 2005, 11, 4444-4450.	3.2	97
12	Differences in Folylpolylglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity. <i>Molecular Pharmacology</i> , 1997, 52, 155-163.	1.0	95
13	Baicalin increases VEGF expression and angiogenesis by activating the ERR α /PGC-1 α pathway. <i>Cardiovascular Research</i> , 2011, 89, 426-435.	1.8	80
14	G-to-T Transversions and Small Tandem Base Deletions Are the Hallmark of Mutations Induced by Ultraviolet A Radiation in Mammalian Cells. <i>Biochemistry</i> , 2004, 43, 8169-8177.	1.2	76
15	A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. <i>Investigational New Drugs</i> , 2008, 26, 249-255.	1.2	76
16	Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. <i>Investigational New Drugs</i> , 2001, 19, 335-340.	1.2	74
17	Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2008, 26, 257-264.	1.2	74
18	Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel. <i>Clinical Cancer Research</i> , 2004, 10, 461-467.	3.2	73

#	ARTICLE	IF	CITATIONS
19	Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2- α -deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 363-368.	1.1	67
20	A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance. <i>Cancer Research</i> , 2013, 73, 6484-6493.	0.4	64
21	Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. <i>Seminars in Oncology</i> , 2003, 30, 14-19.	0.8	61
22	Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function. <i>Clinical Cancer Research</i> , 2007, 13, 4832-4839.	3.2	61
23	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). <i>Investigational New Drugs</i> , 2008, 26, 265-272.	1.2	60
24	Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2163-2169.	0.8	59
25	Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2013, 19, 3631-3639.	3.2	59
26	Advanced Glycation End Products of DNA: Quantification of N ² -(1-Carboxyethyl)-2- α -deoxyguanosine in Biological Samples by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2008, 21, 2148-2155.	1.7	58
27	Neural Stem Cell-Mediated Delivery of Irinotecan-Activating Carboxylesterases to Glioma: Implications for Clinical Use. <i>Stem Cells Translational Medicine</i> , 2013, 2, 983-992.	1.6	58
28	Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. <i>Clinical Cancer Research</i> , 2003, 9, 5896-901.	3.2	57
29	Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. <i>Blood</i> , 2001, 97, 2839-2845.	0.6	50
30	Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 3660-3666.	3.2	48
31	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 1034-1044.	3.2	48
32	Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 103-109.	0.9	46
33	A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for <i>Agaricus bisporus</i> -induced prostate-specific antigen responses. <i>Cancer</i> , 2015, 121, 2942-2950.	2.0	44
34	Iron chelators induce autophagic cell death in multiple myeloma cells. <i>Leukemia Research</i> , 2014, 38, 988-996.	0.4	40
35	Stability and Antibacterial Activity of Cefepime during Continuous Infusion. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1991-1994.	1.4	38
36	Similar Mutagenicity of Photoactivated Porphyrins and Ultraviolet A Radiation in Mouse Embryonic Fibroblasts: Involvement of Oxidative DNA Lesions in Mutagenesis. <i>Biochemistry</i> , 2004, 43, 15557-15566.	1.2	36

#	ARTICLE	IF	CITATIONS
37	Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts. <i>Free Radical Biology and Medicine</i> , 2013, 57, 162-175.	1.3	36
38	HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
39	Single-cell RNA-sequencing analysis of estrogen- and endocrine-disrupting chemical-induced reorganization of mouse mammary gland. <i>Communications Biology</i> , 2019, 2, 406.	2.0	36
40	Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. <i>Clinical Cancer Research</i> , 2007, 13, 1232-1237.	3.2	35
41	A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), Tj ETQq1 1 0.784314 rgBT Cancer Chemotherapy and Pharmacology, 2012, 69, 835-843.	1.1	35
42	Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 103-110.	1.1	31
43	Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma. <i>Frontiers in Oncology</i> , 2019, 9, 68.	1.3	30
44	Molecular Mechanisms of Polybrominated Diphenyl Ethers (BDE-47, BDE-100, and BDE-153) in Human Breast Cancer Cells and Patient-Derived Xenografts. <i>Toxicological Sciences</i> , 2019, 169, 380-398.	1.4	30
45	Phase I study of nelfinavir in liposarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 791-799.	1.1	29
46	Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 617-625.	1.1	29
47	EVEREST: Everolimus for renal cancer ensuing surgical therapy A phase III study (SWOG S0931,) Tj ETQq1 1 0.784314 rgBT / Overlock 0.8	0.8	29
48	Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. <i>JAMA Oncology</i> , 2020, 6, 1947.	3.4	28
49	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 897-907.	1.1	27
50	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. <i>Clinical Cancer Research</i> , 2018, 24, 6053-6065.	3.2	27
51	Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib. <i>Cancer Investigation</i> , 2008, 26, 53-59.	0.6	26
52	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1089-1096.	1.1	24
53	A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5394-5399.	3.3	23
54	A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. <i>Journal of Neuro-Oncology</i> , 2014, 118, 169-177.	1.4	22

#	ARTICLE	IF	CITATIONS
55	Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 533-544.	1.7	21
56	Role of Folylpolypoglutamate Synthetase (FPGS) in Antifolate Chemotherapy; a Biochemical and Clinical Update. <i>Leukemia and Lymphoma</i> , 1996, 21, 9-15.	0.6	19
57	Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age. <i>Oncologist</i> , 2015, 20, 37-44.	1.9	18
58	Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 67-76.	2.0	18
59	A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. <i>European Journal of Cancer</i> , 2013, 49, 1634-1640.	1.3	16
60	Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 495-503.	1.1	16
61	A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 589-598.	1.1	16
62	In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17535-17542.	3.3	15
63	Renoprotective and Lipid-Lowering Effects of LR Compounds, Novel Advanced Glycation End Product Inhibitors, in Streptozotocin-Induced Diabetic Rats. <i>Annals of the New York Academy of Sciences</i> , 2005, 1043, 767-776.	1.8	14
64	Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 927-933.	1.1	14
65	A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1347-1355.	0.8	14
66	Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. <i>British Journal of Cancer</i> , 2014, 111, 2268-2274.	2.9	14
67	Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. <i>Blood Advances</i> , 2019, 3, 1027-1032.	2.5	14
68	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. Relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. <i>Journal of Clinical Laboratory Analysis</i> , 2003, 17, 184-194.	0.9	13
69	Oblimersen and \pm -interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 705-711.	1.2	13
70	Antivirulence Potential of TR-700 and Clindamycin on Clinical Isolates of <i>Staphylococcus aureus</i> Producing Phenol-Soluble Modulins. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4432-4435.	1.4	13
71	Bioimaging Real-Time PXR-Dependent <i>mdr1a</i> Gene Regulation in <i>mdr1a</i> .fLUC Reporter Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 438-445.	1.3	13
72	8- β -chloroadenosine activity in FLT3-ITD acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2019, 234, 16295-16303.	2.0	12

#	ARTICLE	IF	CITATIONS
73	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	0.8	12
74	Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1149-1155.	1.1	11
75	High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 504-508.	1.1	10
76	Development of Population Pharmacokinetic Models and Optimal Sampling Times for Ibuprofen Tablet and Suspension Formulations in Children With Cystic Fibrosis. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 315-321.	1.0	10
77	Effect of valsopodar on the pharmacokinetics of unbound paclitaxel. <i>Investigational New Drugs</i> , 2003, 21, 291-298.	1.2	10
78	Tigecycline Induction of Phenol-Soluble Modulins by Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4562-4565.	1.4	10
79	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 327-332.	1.1	9
80	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 353-359.	1.1	9
81	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 283-289.	1.1	9
82	A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 403-410.	1.1	8
83	Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2043-2054.	0.9	8
84	Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). <i>Kidney Cancer</i> , 2019, 3, 111-118.	0.2	8
85	Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies primarily confined to the peritoneal cavity.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2553-2553.	0.8	8
86	Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96h for the treatment of advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 241-248.	1.1	7
87	Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 101.	2.2	7
88	Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients. <i>Cancer Gene Therapy</i> , 2021, 28, 294-306.	2.2	7
89	A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase, in acute leukemias: a California Cancer Consortium study. <i>Leukemia and Lymphoma</i> , 2016, 57, 2307-2314.	0.6	6
90	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e667-e672.	0.2	6

#	ARTICLE	IF	CITATIONS
91	A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 723-732.	1.1	5
92	A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 549-557.	1.1	4
93	A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. <i>British Journal of Haematology</i> , 2018, 180, 445-448.	1.2	4
94	Pharmacologic Basis for High-dose Chemotherapy. , 0, , 287-315.		4
95	The Effect of Height on Paclitaxel Nerve Damage. <i>Journal of Neuro-Oncology</i> , 2005, 74, 207-210.	1.4	3
96	A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 85-91.	1.1	3
97	Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. <i>Oncologist</i> , 2017, 22, 1189-1196.	1.9	3
98	Phase I/II first-in-human CAR Tâ€“targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1130-TPS1130.	0.8	3
99	Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1996, 683, 245-249.	1.7	2
100	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. <i>Oncologist</i> , 2019, 24, 1137-1145.	1.9	2
101	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 485-489.	0.7	2
102	Development and validation of an LCâ€“MS/MS generic assay platform for small molecule drug bioanalysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114185.	1.4	2
103	Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. <i>Pleura and Peritoneum</i> , 2022, 7, 169-177.	0.5	2
104	Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo. <i>Blood</i> , 2020, 136, 22-23.	0.6	0